Bristol-Myers Squibb (BMY)

Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.

BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.

Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein 41st Annual Strategic Decisions Conference May 28, 2025 3:30 PM ET Company Participants Chris Boerner - Chief Executive Officer & Chairman Conference...

Bristol Myers Squibb's much needed correction has brought the stock back to earth, nearer to its 1Y means while triggering the expanded forward dividend yields. Its dividend investment thesis appears ...

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications.

Bristol-Myers Squibb Company appears deeply undervalued, despite business headwinds and revenue declines from legacy products facing generic competition. The market is already pricing in revenue and E...

I reiterate my buy rating on Bristol-Myers, seeing significant undervaluation despite persistent weak technicals and sector underperformance. BMY's strong earnings beats, high free cash flow yield, an...

Despite socio-economic challenges and pressure from the generic versions of Revlimid and Abraxane, Bristol-Myers Squibb Company's financial position continues to improve. It raised its 2025 diluted EP...